Merck's Stock Dip Offers a Buying Opportunity: Here's Why
Merck & Co., Inc. TodayMRKMerck & Co., Inc.99.14▼134.58Add to WatchlistGlobal big pharmaceutical company Merck & Co. Inc. NYSE: MRK shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024 guidance sank the stock. Its cancer drugs had a stellar performance, but weakness in its Chinese business caused it to cut guidance. Investors can consider t ...